Oslo, Norway, 29 November 2023 - Circio Holding ASA (OSE: CRNA) Circio's
management invites to a live R&D webinar featuring a KOL presentation by
circular RNA pioneer and founder of oRNA Therapeutics, Dr. Alexander
Wesselhoeft, today at 10am EST / 4pm CET.

Webinar details:

Date:    Wednesday 29 November 2023
Time:    10am EST / 4pm CET, duration ~75-90 minutes
Webinar  Click here for webinar link (https://teams.microsoft.com/l/meetup
link:    -join/19%3ameeting_OGNlNmM1ZjMtMmI5Zi00ZTM0LWJiOTAtYzUyNmE4OWE1Zjcx%4
         0thre
         ad.v2/0?context=%7b%22Tid%22%3a%2266b0661a-3ec3-48a8-a966
         -5b0cce82b3fe%22%2c%22Oid%22%3a%22f1f4b1fb-51b3-4160-8c7e
         -64dc6bdf46bb%22%7d)

In the webinar CircioŽs management will provide a company update and review of
the circVec R&D program, and Dr. Wesselhoeft will provide a general perspective
on circRNA biology and the market landscape.

Agenda:

                  Dr. Erik D Wiklund, CEO Circio
 1. Introduction
& company update
                  Dr. R. Alexander Wesselhoeft, Director of RNA Therapeutics,
 2. circRNA KOL   Gene and Cell Therapy Institute, Mass General Brigham,
presentation      Cambridge USA
                  Dr. Victor Levitsky, CSO Circio
 3. Circio R&D
strategy
                  Dr. Thomas B Hansen, VP & Head of Research Circio
 4. circVec R&D
update

Questions can be submitted in advance to renate.birkeli@circio.com or directly
during the live webinar.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@circio.com (renate.birkeli@targovax.com)

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA and
immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform to develop novel
circRNA medicines for rare disease, vaccines, and cancer. The proprietary
circVec technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA from DNA and viral vectors, which can be
deployed for many purposes. The circVec platform has demonstrated enhanced and
more durable protein expression than classic mRNA vector systems, and has the
potential to become the new gold-standard for DNA and virus-based therapeutics
in the future. The circRNA R&D activities are being conducted by the wholly
owned subsidiary Circio AB based at the Karolinska Institute in Stockholm,
Sweden.

In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver
mutations. TG01 is currently being tested in two clinical trials in RAS-mutated
pancreatic cancer and multiple myeloma in the USA and Norway. These studies are
being run through academic collaborative networks, supported by prestigious
research grants from Innovation Norway and the Norwegian Research Council,
creating read-outs and future optionality for the program at low cost to Circio.